Bruker Corp BRKR
2 targets with a reported result
Releases of the last 3 yearsThe numbers BRKR said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $2.10 to $2.15 release Feb 12, 2026
Kept $2.10 to $2.15 release May 6, 2026
Kept $2.10 to $2.15 release Aug 4, 2026
Kept $2.10 to $2.15 release Nov 4, 2026
|
– | No standard number | |
The company's wordsBruker expects FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. release Feb 12, 2026 Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. release May 6, 2026 Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year, now at an effective non-GAAP tax rate of 27.5%. release Aug 4, 2026 Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. release Nov 4, 2026 | ||||
| Diluted EPS (company-defined) Fiscal 2025 (ended Dec 31, 2025) |
Given $2.67 to $2.72 release Feb 13, 2025
Lowered $2.40 to $2.48 release May 7, 2025
Lowered $1.95 to $2.05 release Aug 4, 2025
Lowered $1.85 to $1.90 release Nov 3, 2025
|
– | No standard number | |
The company's wordsBruker initiates FY 2025 guidance (with percentages year-over-year): … Non-GAAP EPS of $2.67 to $2.72; up 11% to 13%, with CER increase of 14% to 16% release Feb 13, 2025 Updated FY 2025 guidance: … Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy release May 7, 2025 Bruker now expects FY 2025 non-GAAP EPS of $1.95 to $2.05, compared to FY 2024 non-GAAP EPS of $2.41. release Aug 4, 2025 Bruker now expects FY 2025 non-GAAP EPS of $1.85 to $1.90, compared to FY 2024 non-GAAP EPS of $2.41. release Nov 3, 2025 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $3.47B to $3.54B release Feb 13, 2025
Raised $3.48B to $3.55B release May 7, 2025
|
$3.44B 10-K filed 2026-02-27 |
Below the range | |
The company's wordsBruker initiates FY 2025 guidance (with percentages year-over-year): … Revenue $3.47 to $3.54 billion; up 3% to 5%, with CER growth of 5% to 7% release Feb 13, 2025 Updated FY 2025 guidance: … Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% release May 7, 2025 | ||||
| Diluted EPS (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $2.71 to $2.76 release Feb 13, 2024
Raised $2.79 to $2.84 release May 2, 2024
Lowered $2.59 to $2.64 release Aug 6, 2024
Lowered $2.36 to $2.41 release Nov 5, 2024
|
– | No standard number | |
The company's wordsBruker expects FY 2024 non-GAAP EPS of $2.71 to $2.76, or 5% to 7% growth yoy. release Feb 13, 2024 Updated FY 2024 guidance: … Non-GAAP EPS of $2.79 to $2.84, up $0.08 from prior guidance, including ELITech EPS accretion, but excluding still pending EPS-dilutive NanoString acquisition release May 2, 2024 Bruker now expects FY 2024 non-GAAP EPS of $2.59 to $2.64, compared to FY 2023 non-GAAP EPS of $2.58. release Aug 6, 2024 Updated FY2024 guidance: … Non-GAAP EPS of $2.36 - $2.41 release Nov 5, 2024 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $3.29B to $3.35B release May 2, 2024
Raised $3.38B to $3.44B release Aug 6, 2024
Lowered $3.34B to $3.37B release Nov 5, 2024
|
$3.37B 10-K filed 2025-03-03 |
Within the range | |
The company's wordsBruker now expects FY 2024 revenues of $3.29 to $3.35 billion, up $60 million from our prior guidance of $3.23 to $3.29 billion. release May 2, 2024 Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy release Aug 6, 2024 Updated FY2024 guidance: … Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth of 3% to 4%, and CER revenue growth of approximately 13% yoy release Nov 5, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-02-13), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.